Mike Zumdahl

Founded and lead a MedTech consultancy guiding start-ups on go-to-market, reimbursement, FDA breakthrough pathways, and commercial team recruitment to accelerate adoption and revenue growth.

Led global market access, reimbursement, HEOR, and government affairs teams, shaping commercial strategy, pricing, and evidence generation to grow and protect global reimbursement for the portfolio prior to acquisition.

Owned U.S. contracting, pricing, and sales strategy for government payers and PBMs for the first FDA-approved implantable CGM, developing national payer strategy and commercial account management capabilities.

Managed government payer contracts driving $350M annually, led HEOR and value-based contracting initiatives, and deployed analytics tools to inform market access and sales decisions.

Supported regional operations delivering $150M annually, managed a $2.4M budget and led sales execution, training, and Lean Six Sigma initiatives to improve regional performance.

Managed IDN and hospital accounts, leading cross-functional efforts to secure formulary wins and large-group exclusivity for insulin products.

Exceeded regional sales goals by developing customer relationships and executing promotional and incentive programs to increase patient uptake of therapies.

Managed hospital system accounts across multiple specialties, led national and regional sales training initiatives, and consistently exceeded sales goals.

Responsible for new business acquisition and customer service in the Midwest, achieving Sales Representative of the Year honors in 2005.

Managed NIH and FDA federal accounts, building relationships with purchasing directors and investigators to increase sales and manage promotional programs.

Completed a Bachelor of Science degree in Education with coursework preparing for K–12 teaching and classroom management.

Activities and societies: NCAA Division I Track & Field (Decathlon)

Participated in NCAA Division I Track & Field as a decathlete while enrolled in undergraduate studies.